Elevation Pharma raises $30 million for COPD candidate
This article was originally published in Scrip
Executive Summary
Elevation Pharmaceuticals has closed its series A financing round, raising $30 million from a syndicate of investors for the development of its long-acting bronchodilator EP-101.